Rivastigmine Tartrate Capsule
Product Images NDC 62135-902

Product Visual Gallery

This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Rivastigmine Tartrate (NDC 62135-902). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Chartwell Rx, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Rivastigmine-fig-1 (Rivastigmine Fig 1)

A line graph depicting clinical improvement and decline over 26 weeks of treatment with rivastigmine tartrate capsules. The x-axis represents weeks during treatment, and the y-axis shows mean change from baseline on a clinical scale. Three groups are shown: 6-12 mg dose, 1-4 mg dose, and placebo, with clinical improvement associated with higher doses and decline with lower doses and placebo.*

FDA Label Image

Rivastigmine-fig-2 (Rivastigmine Fig 2)

A line graph showing the cumulative percentage of patients versus change from baseline on the ADAS-cog scale. The graph compares three groups: placebo, 1-4 mg/day, and 6-12 mg/day doses of rivastigmine tartrate, with markers indicating these categories over a change range from around -20 to +30. An inset table summarizes changes in ADAS-cog scores at 7 and 48 months for treatment and placebo groups.*

FDA Label Image

Rivastigmine-fig-3 (Rivastigmine Fig 3)

A bar chart showing CGIBC-Plus ratings comparing placebo and two doses (1-4 mg and 6-12 mg) of a drug. The categories on the x-axis are Markedly Improved, Moderately Improved, Minimally Improved, Unchanged, Minimally Worse, Moderately Worse, and Markedly Worse, with percentage of patients on the y-axis. Different bars represent each treatment group across these outcome categories.*

FDA Label Image

Rivastigmine-fig-4 (Rivastigmine Fig 4)

Line graph depicting mean change from baseline in ADAS-cog score over 26 weeks of treatment, comparing 6-12 mg and 1-4 mg Rivastigmine Tartrate doses to placebo. The x-axis shows weeks during treatment, and the y-axis indicates score change, with thresholds for clinical improvement and decline.*

FDA Label Image

Rivastigmine-fig-5 (Rivastigmine Fig 5)

A cumulative patients plot displaying change from baseline on the x-axis and cumulative percentage of patients on the y-axis. The graph compares three groups—6-12 mg, 1-4 mg, and placebo—showing their change in ADAS-cog scores with marked points for 7 and 10 points of change, illustrating differing treatment effects.*

FDA Label Image

Rivastigmine-fig-6 (Rivastigmine Fig 6)

A bar chart showing the distribution of patients by CIBIC-Plus rating categories, comparing three groups: Placebo, 1-4 mg dosage, and 6-12 mg dosage. The categories range from Markedly Improved to Markedly Worse, with the highest percentages observed in the Unchanged group for all treatments.*

FDA Label Image

Rivastigmine-fig-7 (Rivastigmine Fig 7)

Line graph depicting clinical outcomes over 24 weeks of treatment comparing Rivastigmine tartrate capsule and placebo. The y-axis measures mean change from baseline ADAS-Cog rating, with Rivastigmine showing clinical improvement and placebo illustrating clinical decline over time.*

FDA Label Image

Rivastigmine-fig-8 (Rivastigmine Fig 8)

A bar chart comparing the ADCS-CGIC (Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change) rating percentages of patients taking Rivastigmine tartrate capsules versus placebo. The categories range from markedly improved to markedly worse, showing the distribution of patient outcomes in both groups.*

FDA Label Image

Rivastigmine-tartrate (Rivastigmine Structure)

Chemical structure of Rivastigmine Tartrate, depicting the molecular framework including aromatic rings, ester and amide functional groups, and the tartrate moiety indicated by .C4H6O6.*

FDA Label Image

Rivastigmine-tartrate-1pt5mg-bottle-label (Rivastigmine Tartrate 1pt5mg Bottle Label)

Label for Rivastigmine Tartrate 1.5 mg capsules, USP, oral dosage form. The label states the product contains 60 capsules and is distributed by Chartwell RX, LLC. Storage and usage instructions include temperature limits and advising to see the package insert for dosage. The label features the NDC 62135-900-60, barcode, and a 'No Varnish' marking.*

FDA Label Image

Rivastigmine-tartrate-3mg-bottle-label (Rivastigmine Tartrate 3mg Bottle Label)

Label for Rivastigmine Tartrate Capsules USP 3 mg by Chartwell RX, LLC. The label indicates 60 capsules per bottle, prescription use only. Storage instructions and manufacturer details are provided, with the NDC 62135-901-60. The label includes a barcode and states 'No Varnish'.*

FDA Label Image

Rivastigmine-tartrate-4pt5mg-bottle-label (Rivastigmine Tartrate 4pt5mg Bottle Label)

Rivastigmine Tartrate 4.5 mg capsules label from Chartwell RX, LLC. The label indicates the product is for prescription use only, with 60 capsules per container. Storage instructions and caution about temperature excursions are provided. The label includes the NDC 62135-902-60 and a barcode.*

FDA Label Image

Rivastigmine-tartrate-6mg-bottle-label (Rivastigmine Tartrate 6mg Bottle Label)

Rivastigmine Tartrate Capsules USP 6 mg, oral dosage form, packaged by Chartwell RX, LLC. The label states Rx Only and indicates a quantity of 60 capsules. It includes storage instructions, usual dosage guidance, and warnings to keep the medication out of children's reach. The label features a barcode and mentions the product is made in the USA.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.